| ID | Sequence | Length | GC content |
|---|---|---|---|
| AGUCCCUAUUUGGAACUGCUCUCGCGGCAGUUCAGACCUCGUGCUCGUC… | 5736 nt | 0.5898 | |
| AGUCCCUAUUUGGAACUGCUCUCGCGGCAGUUCAGACCUCGUGCUCGUC… | 5721 nt | 0.5899 | |
| AGUCCCUAUUUGGAACUGCUCUCGCGGCAGUUCAGACCUCGUGCUCGUC… | 5730 nt | 0.5895 | |
| AUUUAAGCAUCUAUCAUGGCAGGGUAAACGAGGCAGUUUAUCUGGCACC… | 4669 nt | 0.5545 | |
| ACAUAAUAUAACGUUCUGUUGAGAUGAGAGGAACGCUCGCCCUUGUCAG… | 4480 nt | 0.5565 | |
| AGUCCCUAUUUGGAACUGCUCUCGCGGCAGUUCAGACCUCGUGCUCGUC… | 5745 nt | 0.5894 | |
| AGUCCCUAUUUGGAACUGCUCUCGCGGCAGUUCAGACCUCGUGCUCGUC… | 5709 nt | 0.5898 |
This gene encodes a transcriptional co-repressor protein that belongs to the transducin-like enhancer family of proteins. The members of this family function in the Notch signaling pathway that regulates determination of cell fate during development. Expression of this gene has been associated with a favorable outcome to chemotherapy with taxanes for ovarian carcinoma. Alternate splicing results in multiple transcript variants. Additional alternatively spliced transcript variants of this gene have been described, but their full-length nature is not known. [provided by RefSeq, Sep 2013]
A study in rats demonstrated that the TLE3 (Tle3) was identified as a potential regulator of methamphetamine reward and addiction through transcriptome profiling of whisker follicles, where its expression was down-down regulated (0.70 at MASA, 0.35 at WD) and it was prioritized via topological network analysis with a betweenness centrality score of 0.0134 [Song et al. DOI:10.1038/s41598-018-29772-1].